My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
LT Foods jumps after acquiring a rice brand
Jul 18,2016

The announcement was made on Saturday, 16 July 2016.

Meanwhile, the S&P BSE Sensex was up 147.31 points or 0.53% at 27,983.81.

On BSE, so far 31,000 shares were traded in the counter as against average daily volume of 8,333 shares in the past one quarter. The stock hit a high of Rs 306.85 and a low of Rs 288.90 so far during the day. The stock had hit a record high of Rs 314.40 on 24 November 2015. The stock had hit a 52-week low of Rs 144 on 25 August 2015. The stock had outperformed the market over the past one month till 15 July 2016, gaining 20.66% compared with Sensexs 4.15% rise. The scrip had also outperformed the market in past one quarter, advancing 27.25% as against Sensexs 8.62% rise.

The small-cap company has equity capital of Rs 26.66 crore. Face value per share is Rs 10.

On consolidated basis, LT Foods net profit fell 74.4% to Rs 5.55 crore on 14% growth in net sales to Rs 805.13 crore in Q4 March 2016 over Q4 March 2015.

LT Foods offers branded basmati rice, value-added staples and organic food. L T Foods operations include contract farming, procurement, storage, processing, packaging and distribution. It is also engaged in research and development to add value to rice and rice food products.

Powered by Capital Market - Live News

Dr Reddys Labs gains after launching drug in US market
Jul 18,2016

The announcement was made during trading hours today, 18 July 2016.

Meanwhile, the BSE Sensex was up 148.24 points, or 0.55%, to 27,989.36.

On BSE, so far 5,225 shares were traded in the counter, compared with an average volume of 30,517 shares in the past one quarter. The stock hit a high of Rs 3,610.80 and a low of Rs 3,563.95 so far during the day. The stock hit a record high of Rs 4,382.95 on 20 October 2015. The stock hit a 52-week low of Rs 2,750 on 21 January 2016. The stock had outperformed the market over the past one month till 15 July 2016, rising 16.14% compared with 4.15% rise in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 15.56% as against Sensexs 8.62% rise.

The large-cap company has an equity capital of Rs 85.35 crore. Face value per share is Rs 5.

Dr Reddys Laboratories announced that it has launched Omeprazole and Sodium bicarbonate capsules, 20mg/1100mg and 40mg/1100mg, a therapeutic equivalent generic version of ZEGERID (omeprazole/ sodium bicarbonate) capsules in the United States market, having been approved by the US Food & Drug Administration (USFDA). The Zegerid brand and generic had US sales of approximately $306.7 million MAT for the most recent twelve months ended in May 2016 according to MS HeaIth. Dr. Reddys Omeprazole and sodium bicarbonate capsules 20mg/1100mg and 40mg/1100mg are available in bottle count size of 30. Zegerid is a registered trademark of Santarus, Inc. a wholly-owned subsidiary of Salk Pharmaceuticals, Inc.

Meanwhile, Dr Reddys Laboratories turned ex-dividend today, 18 July 2016 for dividend of Rs 20 per share for the year ended 31 March 2016 (FY 2016).

Dr Reddys Laboratories consolidated net profit fell 85.6% to Rs 74.60 crore on 3% decline in net sales to Rs 3756.20 crore in Q4 March 2016 over Q4 March 2015.

Dr Reddys Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr Reddys offers a portfolio of products and services including active pharmaceutical ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Powered by Capital Market - Live News

Den Networks moves higher after increasing stake in Macro Commerce
Jul 18,2016

The announcement was made after market hours on Friday, 15 July 2016.

Meanwhile, the S&P BSE Sensex was up 157.17 points or 0.56% at 27,993.67.

On BSE, so far 33,000 shares were traded in the counter as against average daily volume of 17,407 shares in the past one quarter. The stock hit a high of Rs 94.70 and a low of Rs 90.25 so far during the day. The stock had hit a 52-week high of Rs 169 on 20 July 2015. The stock had hit a 52-week low of Rs 60.50 on 15 February 2016. The stock had underperformed the market over the past one month till 15 July 2016, gaining 0.11% compared with Sensexs 4.15% rise. The scrip had also underperformed the market in past one quarter, sliding 4.38% as against Sensexs 8.62% rise.

The small-cap company has equity capital of Rs 178.20 crore. Face value per share is Rs 10.

Den Networks has entered into an agreement with Jasper Infotech for purchase of shares worth Rs 1 crore in Macro Commerce (Macro) and subscription by way of rights issue totaling Rs 5 crore.

Den Networks currently holds 32.87% stake in Macro and post acquisition it will increase to 82.87%.

Macro reported turnover of Rs 28 crore in the financial year ended 31 March 2016.

On consolidated basis, Den Networks reported net loss of Rs 85.44 crore in Q4 March 2016, higher than net loss of Rs 62.08 crore in Q4 March 2015. Net sales rose 38.3% to Rs 361.76 crore in Q4 March 2016 over Q4 March 2015.

Den Networks is one of leading cable TV distribution companies in India.

Powered by Capital Market - Live News

SPARC jumps after licensing arrangement with Sun Pharma
Jul 18,2016

Separate announcements were made by Sun Pharmaceutical Industries and Sun Pharma Advanced Research Company before market hours today, 18 July 2016.

Shares of Sun Pharmaceutical Industries rose 0.82% to Rs 776.70.

Meanwhile, the BSE Sensex was up 158.77 points, or 0.57%, to 27995.27.

On BSE, so far 42,517 shares were traded in the counter of Sun Pharma Advanced Research Company (SPARC), compared with an average volume of 91,937 shares in the past one quarter. The stock hit a high of Rs 374.90 and a low of Rs 359.80 so far during the day. The stock hit a 52-week high of Rs 446.84 on 17 July 2015. The stock hit a 52-week low of Rs 243.43 on 25 February 2016. The stock had outperformed the market over the past one month till 15 July 2016, rising 23.01% compared with 4.15% rise in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 20.28% as against Sensexs 8.62% rise.

The mid-cap company has an equity capital of Rs 24.69 crore. Face value per share is Re 1.

Sun Pharma Advanced Research Company (SPARC) and Sun Pharmaceutical Industries announced a licensing arrangement for SPARCs ELEPSIA XR (Levetiracetam Extended Release tablets). As per the agreement, SPARC will license ELEPSIA XR (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary of Sun Pharma for the US market. SPARC will receive an up-front payment of $10 million from Sun Pharma. It is also eligible for certain additional milestone payments and defined royalties linked to any future sales of ELEPSIA XR.

ELEPSIA XR was approved by the United States Food & Drug Administration (USFDA) in March 2015. However, in September 2015, SPARC received a complete response letter (CRL) from the USFDA rescinding its earlier approval, citing that the compliance status of the manufacturing facility viz., Halol site of Sun Pharma was not acceptable on the date of approval. Sun Pharma has undertaken a detailed remediation at Halol for restoring cGMP compliance status for the site.

Levetiracetam products currently approved by FDA and available in the US market are generally indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy. As per IMS MAT December 2015, 9 million prescriptions were dispensed for Levetiracetam making it one of the most widely prescribed treatments for epilepsy in the US.

Anil Raghavan, CEO, SPARC said that the licensing of ELEPSIA XR is a step ahead in companys desire to make it available for thousands of epilepsy patients taking multiple pills of Levetiracetam every day. ELEPSIA XR is designed as a novel once-a-day formulation of Levetiracetam using SPARCs proprietary Wrap Matrix technology. It is designed to reduce pill burden and help improve convenience and compliance in these patients. If and when the USFDA reapproves the ELEPSIA XR application, Sun Pharmas significant US presence will help SPARC in commercializing this important product for patients in the US market.

Commenting on the in-licensing, Kirti Ganorkar, Senior Vice President, Business Development, Sun Pharma said that the in-licensing of ELEPSIA XR will facilitate Sun Pharmas anticipated entry into the proprietary CNS segment in the US. This is a part of Sun Pharmas strategy, to strengthen its presence in the US specialty segment through its newly created Sun Neurosciences business unit.

SPARC reported net loss of Rs 9.58 crore in Q4 March 2016 compared with net loss of Rs 9.40 crore in Q4 March 2015. Net sales dropped 3.6% to Rs 41.17 crore in Q4 March 2016 over Q4 March 2015.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Powered by Capital Market - Live News

SPARC jumps after entering into licensing arrangement with Sun Pharma
Jul 18,2016

Separate announcements were made by Sun Pharmaceutical Industries and Sun Pharma Advanced Research Company before market hours today, 18 July 2016.

Shares of Sun Pharmaceutical Industries rose 0.82% to Rs 776.70.

Meanwhile, the BSE Sensex was up 158.77 points, or 0.57%, to 27995.27.

On BSE, so far 42,517 shares were traded in the counter of Sun Pharma Advanced Research Company (SPARC), compared with an average volume of 91,937 shares in the past one quarter. The stock hit a high of Rs 374.90 and a low of Rs 359.80 so far during the day. The stock hit a 52-week high of Rs 446.84 on 17 July 2015. The stock hit a 52-week low of Rs 243.43 on 25 February 2016. The stock had outperformed the market over the past one month till 15 July 2016, rising 23.01% compared with 4.15% rise in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 20.28% as against Sensexs 8.62% rise.

The mid-cap company has an equity capital of Rs 24.69 crore. Face value per share is Re 1.

Sun Pharma Advanced Research Company (SPARC) and Sun Pharmaceutical Industries announced a licensing arrangement for SPARCs ELEPSIA XR (Levetiracetam Extended Release tablets). As per the agreement, SPARC will license ELEPSIA XR (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary of Sun Pharma for the US market. SPARC will receive an up-front payment of $10 million from Sun Pharma. It is also eligible for certain additional milestone payments and defined royalties linked to any future sales of ELEPSIA XR.

ELEPSIA XR was approved by the United States Food & Drug Administration (USFDA) in March 2015. However, in September 2015, SPARC received a complete response letter (CRL) from the USFDA rescinding its earlier approval, citing that the compliance status of the manufacturing facility viz., Halol site of Sun Pharma was not acceptable on the date of approval. Sun Pharma has undertaken a detailed remediation at Halol for restoring cGMP compliance status for the site.

Levetiracetam products currently approved by FDA and available in the US market are generally indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy. As per IMS MAT December 2015, 9 million prescriptions were dispensed for Levetiracetam making it one of the most widely prescribed treatments for epilepsy in the US.

Anil Raghavan, CEO, SPARC said that the licensing of ELEPSIA XR is a step ahead in companys desire to make it available for thousands of epilepsy patients taking multiple pills of Levetiracetam every day. ELEPSIA XR is designed as a novel once-a-day formulation of Levetiracetam using SPARCs proprietary Wrap Matrix technology. It is designed to reduce pill burden and help improve convenience and compliance in these patients. If and when the USFDA reapproves the ELEPSIA XR application, Sun Pharmas significant US presence will help SPARC in commercializing this important product for patients in the US market.

Commenting on the in-licensing, Kirti Ganorkar, Senior Vice President, Business Development, Sun Pharma said that the in-licensing of ELEPSIA XR will facilitate Sun Pharmas anticipated entry into the proprietary CNS segment in the US. This is a part of Sun Pharmas strategy, to strengthen its presence in the US specialty segment through its newly created Sun Neurosciences business unit.

SPARC reported net loss of Rs 9.58 crore in Q4 March 2016 compared with net loss of Rs 9.40 crore in Q4 March 2015. Net sales dropped 3.6% to Rs 41.17 crore in Q4 March 2016 over Q4 March 2015.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Powered by Capital Market - Live News

Cox & Kings surges after fund buying
Jul 18,2016

Meanwhile, the S&P BSE Sensex was up 166.07 points or 0.6% at 28,002.57.

On BSE, so far 2.04 lakh shares were traded in the counter as against average daily volume of 95,002 shares in the past one quarter. The stock hit a high of Rs 213.80 and a low of Rs 204.10 so far during the day. The stock had hit a 52-week high of Rs 317 on 5 August 2015. The stock had hit a 52-week low of Rs 140.50 on 17 February 2016. The stock had outperformed the market over the past one month till 15 July 2016, gaining 25.59% compared with Sensexs 4.15% rise. The scrip had, however, underperformed the market in past one quarter, advancing 7.11% as against Sensexs 8.62% rise.

The small-cap company has equity capital of Rs 88.28 crore. Face value per share is Rs 5.

On consolidated basis, Cox & Kings reported net loss of Rs 305.54 crore in Q4 March 2016 compared with net profit of Rs 64.57 crore in Q4 March 2015. Net sales declined 3% to Rs 469.41 crore in Q4 March 2016 over Q4 March 2015.

Cox & Kings is one of the longest established travel companies in the world since 1758. Headquartered in India, it is the leading holidays and education travel group with operations in 22 countries across 4 continents.

Powered by Capital Market - Live News

Bharti Airtel drops after reducing pre-paid data tariffs
Jul 18,2016

The announcement was made yesterday, 17 July 2016.

Meanwhile, the S&P BSE Sensex was up 136.22 points or 0.49% at 27,972.72.

On BSE, so far 27,000 shares were traded in the counter as against average daily volume of 2.19 lakh shares in the past one quarter. The stock hit a high of Rs 380 and a low of Rs 375.70 so far during the day. The stock had hit a 52-week high of Rs 452.45 on 21 July 2015. The stock had hit a 52-week low of Rs 282.30 on 29 January 2016. The stock had outperformed the market over the past one month till 15 July 2016, gaining 7.59% compared with Sensexs 4.15% rise. The scrip had, however, underperformed the market in past one quarter, advancing 7.59% as against Sensexs 8.62% rise.

The large-cap company has equity capital of Rs 1998.70 crore. Face value per share is Rs 5.

Bharti Airtel announced an effective reduction in pre-paid data tariffs by increasing data benefits on some of its pre-paid data recharge packs with effect from 17 July 2016. Airtel customers will now enjoy more value on these existing packs and can add to their mobile internet experience by staying online longer and download more of their favorite content, the company said.

Under the revised data benefits, the Rs 655 4G/3G monthly recharge pack will now offer 5 GB data vs 3 GB earlier, an increase of 67%. Similarly, the Rs 455 pack 4G/3G pack now offers 50% more data by increasing data benefit to 3 GB from 2 GB. The Rs 989 4G/3G pack will now offer 10 GB data vs 6.5 GB earlier, offering 54% more benefits. 2G/3G/4G Sachet Packs also see major increase in benefits. The Rs 25 2G pack now offers 45% more data at 145 MB vs 100 MB earlier, while the Rs 145 4G/3G pack now offers 32% more data benefits at 580 MB vs 440 MB earlier. Even the Rs 5 one day 2G data pack benefits have been increased by 48% to 30 MB keeping in mind non-regular/first time users, particularly in rural markets.

Bharti Airtels consolidated net profit rose 2.8% to Rs 1290.30 crore on 8.4% growth in net sales to Rs 24959.60 crore in Q4 March 2016 over Q4 March 2015.

Bharti Airtel ranks amongst the top three mobile service providers globally in terms of subscribers. The company has its operations in 20 countries across Asia and Africa.

Powered by Capital Market - Live News

IDFC Bank gains after RBI nod for hike in foreign investment limit
Jul 18,2016

Meanwhile, the BSE Sensex was up 168.06 points, or 0.60%, to 28,004.56.

On BSE, so far 1.25 lakh shares were traded in the counter, compared with an average volume of 11.65 lakh shares in the past one quarter. The stock hit a high of Rs 52.95 and a low of Rs 51.80 so far during the day. The stock hit a record high of Rs 73.45 on 6 November 2015. The stock hit a record low of Rs 43.15 on 21 January 2016. The stock had outperformed the market over the past one month till 15 July 2016, rising 8.99% compared with 4.15% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 4.72% as against Sensexs 8.62% rise.

The large-cap company has an equity capital of Rs 3394.90 crore. Face value per share is Rs 10.

The Reserve Bank of India on Friday, 15 July 2016 notified that foreign institutional investors (FIIs)/registered foreign portfolios investors (RFPIs) can now enhance investment from existing 24% to 46% of the paid up capital of IDFC Bank under the portfolio investment scheme (PIS). The RBI further notified that the total foreign investment from all sources i.e. foreign institutional investors (FII)/registered foreign portfolios investors (RFPIs)/foreign direct investment (FDI)/non-resident Indians (NRI)/persons of Indian origin (PIO)/American depository receipts (ADR)/Global depository receipts (GDR)/ in IDFC Bank shall not exceed 46%. The RBI has stated that IDFC Bank has passed resolutions at its board of directors level and a special resolution by the shareholders, agreeing for enhancing the limit for the purchase of its equity shares by FIIs/RFPIs. The purchases could be made through primary market and stock exchanges.

IDFC Bank reported net profit of Rs 165.06 crore on operating income of Rs 1953.20 crore in Q4 March 2016.

IDFC Bank is a subsidiary of IDFC. The Reserve Bank of India (RBI) granted a universal banking license to IDFC on 23 July 2015. IDFC demerged on 1 October 2015, transferring all assets and liabilities of its lending business to IDFC Bank. IDFC Financial Holding Company holds 52.95% stake in the bank as per the shareholding pattern as at 5 July 2016. Shares of IDFC Bank listed on the stock exchanges on 6 November 2015.

IDFC Bank is a universal bank, offering financial solutions through its nationwide branches, internet and mobile. IDFC Bank will focus on serving the rural underserved communities and the self-employed, while continuing to support the countrys infrastructure sector. IDFC Bank provides customized financial solutions to corporates, individuals, small and microenterprises, entrepreneurs, financial institutions and the government.

Powered by Capital Market - Live News

RIL gains on strong Q1 results
Jul 18,2016

The result was announced after market hours on Friday, 15 July 2016.

Meanwhile, the S&P BSE Sensex was up 136.95 points or 0.49% at 27,973.45.

On BSE, so far 1.02 lakh shares were traded in the counter as against average daily volume of 2.56 lakh shares in the past one quarter. The stock hit a high of Rs 1,038.15 and a low of Rs 1,025.10 so far during the day.

The large-cap company has equity capital of Rs 3242.71 crore. Face value per share is Rs 10.

Reliance Industries (RIL)s earnings before interest and tax (EBIT) margin rose by 2.41% to 10.7% in Q1 June 2016 from 8.29% in Q1 June 2015. Decline in revenue was led by the 26% decline in benchmark Brent crude oil price which averaged at $45.6 per barrel in Q1 June 2016 as compared to $61.9 per barrel in Q1 June 2015. Impact of lower prices was partially offset by higher volumes in refining and petrochemicals segments. Gross refining margin rose to $11.5 per barrel in Q1 June 2016 from $10.4 per barrel in Q1 June 2015. Profit before depreciation, interest and tax (PBDIT) increased by 16.7% to Rs 13589 crore in Q1 June 2016 over Q1 June 2015. Strong operating performance from refining and petrochemicals businesses coupled with favorable exchange rate movement enhanced the operating profit. This was partially offset by lower contribution from Oil & Gas business due to lower volumes and weak price environment. Other income was higher at Rs 2378 crore in Q1 June 2016 as against Rs 1584 crore in Q1 June 2015 due to higher interest income and profit on sale of investments.

Reliance Jio Infocomm (RJIL), a subsidiary of RIL, is rolling out a state-of-the-art pan India digital services business. The test program of RJILs digital services will be progressively upgraded into commercial operations in coming months.

RIL is a diversified firm having presence in oil exploration, petrochemicals, retail and telecom sectors.

Powered by Capital Market - Live News

Axis Bank gains as RBI raises foreign investment ceiling
Jul 18,2016

Meanwhile, the S&P BSE Sensex was up 142.62 points or 0.51% at 27,979.12.

On BSE, so far 53,000 shares were traded in the counter as against average daily volume of 7.35 lakh shares in the past one quarter. The stock hit a high of Rs 574.50 and a low of Rs 569 so far during the day. The stock had hit a 52-week high of Rs 613.40 on 16 July 2015. The stock had hit a 52-week low of Rs 366.65 on 18 January 2016. The stock had outperformed the market over the past one month till 15 July 2016, gaining 6.86% compared with Sensexs 4.15% rise. The scrip had also outperformed the market in past one quarter, advancing 28.13% as against Sensexs 8.62% rise.

The large-cap private sector bank has equity capital of Rs 477.51 crore. Face value per share is Rs 2.

The Reserve Bank of India (RBI) on Friday, 15 July 2016 notified that Foreign Institutional Investors (FIIs)/Registered Foreign Portfolios Investors (RFPIs) can now invest up to 74% from existing 62% of the paid up capital of the bank under the Portfolio Investment Scheme (PIS). The central bank notified that the total foreign investment in the bank shall not exceed 74% of paid up capital. The RBI has stated that the Axis Bank has passed resolutions at its Board of Directors level and a special resolution by the shareholders, agreeing for enhancing the limit for the purchase of its equity shares and convertible debentures by FIIs/RFPIs. The purchases could be made through primary market and stock exchanges.

Axis Banks net profit fell 1.2% to Rs 2154.28 crore on 9.8% growth in total income to Rs 13592.97 crore in Q4 March 2016 over Q4 March 2015.

Axis Bank is one of the biggest private sector banks in India.

Powered by Capital Market - Live News

Nifty July futures trade at premium to spot price
Jul 15,2016

The July 2016 futures on the Nifty 50 index traded at 8557.15, at a premium of 15.75 points compared with Niftys closing of 8541.40 in the cash market. The Nifty August 2016 futures traded at 8594, at a premium of 52.60 points compared with the spot closing for the index. Turnover on the National Stock Exchanges futures & options (F&O) segment fell to Rs 3.04 lakh crore from turnover of Rs 3.77 lakh crore registered yesterday, 14 July 2016.

In the cash market, the Nifty 50 index fell 23.60 points or 0.28% to settle at 8,541.40, its lowest closing level since 13 July 2016.

Infosys, Tata Steel, TCS, LIC Housing Finance and Punjab National Bank were the top traded individual stock futures contracts in F&O segment of NSE. Infosys July 2016 futures traded at 1,075.65, at a premium compared with spot closing of 1070.75. Tata Steel July 2016 futures traded at 365.25, at a discount compared with spot closing of 372.20. TCS July 2016 futures traded at 2441, at a premium compared with spot closing of 2445.15.

LIC Housing Finance July 2016 futures traded at 529, at a premium compared with spot closing of 526.65. Punjab National Bank July 2016 futures traded at 135.70, at a discount compared with spot closing of 136.40.

The July 2016 F&O contracts are set to expire on 28 July 2016. The August 2016 F&O contracts are set to expire on 25 August 2016.

Powered by Capital Market - Live News

Lloyds Metals gains after fixing record date for stock split
Jul 15,2016

The announcement was made during trading hours today, 15 July 2016.

Meanwhile, the BSE Sensex was down 106.66 points, or 0.38%, to 27,835.45.

On BSE, so far 89,000 shares were traded in the counter, compared with an average volume of 49,225 shares in the past one quarter. The stock hit a high of Rs 30.50 and a low of Rs 28 so far during the day. The stock hit a 52-week high of Rs 34.95 on 12 April 2016. The stock hit a 52-week low of Rs 5.66 on 31 July 2015. The stock had underperformed the market over the past one month till 14 July 2016, rising 0.70% compared with 5.86% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 9.97% as against Sensexs 9.03% rise.

The small-cap company has an equity capital of Rs 22.26 crore. Face value per share is Rs 2.

Earlier in April 2016, the board of Lloyds Metals and Energy had approved splitting each share into two.

Lloyds Metals & Energy reported net loss of Rs 2.63 crore in Q4 March 2016 as against net loss of Rs 2.56 crore in Q4 March 2015. Net sales declined 32.32% to Rs 81.82 crore in Q4 March 2016 over Q4 March 2015.

Lloyds Metals and Energy focuses on manufacturing steel & related products, including upstream (coal-based DRI) & downstream (like engineering products).

Powered by Capital Market - Live News

LIC Housing Finance gains after announcing Q1 results
Jul 15,2016

The result was announced during market hours today, 15 July 2016.

Meanwhile, the S&P BSE Sensex was down 120.90 points or 0.43% at 27,821.21.

On BSE, so far 9.91 lakh shares were traded in the counter as against average daily volume of 2.07 lakh shares in the past one quarter. The stock hit a high of Rs 529.70 and a low of Rs 503.25 so far during the day. The stock had hit a record high of Rs 533 on 12 July 2016. The stock had hit a 52-week low of Rs 25 February 2016. The stock had outperformed the market over the past one month till 14 July 2016, surging 7.85% compared with 5.86% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, advancing 5.36% as against Sensexs 9.03% rise.

The large-cap company has equity capital of Rs 100.93 crore. Face value per share is Rs 2.

LIC Housing Finance is a housing finance company. LIC of India holds 40.31% stake in the firm as on 30 June 2016.

Powered by Capital Market - Live News

L&T gains on plan to sell 15% stake in L&T Technology Services via IPO
Jul 15,2016

The announcement was made during trading hours today, 15 July 2016.

Meanwhile, the BSE Sensex was up 114.96 points, or 0.41%, to 27,827.15.

On BSE, so far 1.64 lakh shares were traded in the counter, compared with an average volume of 2.04 lakh shares in the past one quarter. The stock hit a high of Rs 1,594.95 and a low of Rs 1,558 so far during the day. The stock hit a 52-week high of Rs 1,886.25 on 17 July 2015. The stock hit a 52-week low of Rs 1,016.60 on 12 February 2016. The stock had outperformed the market over the past one month till 14 July 2016, rising 7.07% compared with 5.86% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 26.57% as against Sensexs 9.03% rise.

The large-cap company has an equity capital of Rs 186.40 crore. Face value per share is Rs 2.

L&T Technology Service is a pure play global engineering, research and development services company. Prior to 1 January 2014, the business was conducted as a division of L&T and as a sub-segment business of L&Ts unit, L&T Infotech.

The decision to sell 15% of stake in L&T Technology Services comes two days after L&Ts subsidiary, L&T Infotech, received strong response from investors for its initial public offer (IPO) which concluded on Wednesday, 13 July 2016. IT outsourcing services provider L&T Infotechs IPO received bids for 14.31 crore shares compared to 1.22 crore shares on offer. The IPO was subscribed 11.69 times. The IPO opened for bidding on 11 July 2016. The price band of the IPO was fixed at Rs 705-710 per share.

L&Ts consolidated net profit rose 18.6% to Rs 2453.64 crore on 18.51% rise in net sales to Rs 32812.24 crore in Q4 March 2016 over Q4 March 2015.

L&T is a major Indian multinational engaged in technology, engineering, construction, manufacturing and financial services. It operates in more than 30 countries worldwide.

Powered by Capital Market - Live News

Nava Bharat jumps as board to consider bonus issue
Jul 15,2016

The announcement was made after market hours yesterday, 14 July 2016.

Meanwhile, the S&P BSE Sensex was down 70.54 points or 0.25% at 27,871.57.

On BSE, so far 1.85 lakh shares were traded in the counter as against average daily volume of 52,971 shares in the past one quarter. The stock hit a high of Rs 248 and a low of Rs 240 so far during the day. The stock had hit a 52-week high of Rs 250.85 on 7 July 2016. The stock had hit a 52-week low of Rs 128 on 12 February 2016. The stock had outperformed the market over the past one month till 14 July 2016, surging 24.93% compared with 5.86% rise in the Sensex. The scrip had also outperformed the market in past one quarter, advancing 42.04% as against Sensexs 9.03% rise.

The small-cap company has equity capital of Rs 17.86 crore. Face value per share is Rs 2.

Nava Bharat Ventures net profit surged 136.2% to Rs 57.64 crore on 8% growth in net sales to Rs 302.20 crore in Q4 March 2016 over Q4 March 2015.

Nava Bharat Ventures operates in the business verticals of power generation, mining, ferro alloys and agri-business with multi-national operations spread over India, South East Asia and Africa.

Powered by Capital Market - Live News